Jean Jacques Bienaime - Net Worth and Insider Trading
Jean Jacques Bienaime Net Worth
The estimated net worth of Jean Jacques Bienaime is at least $46 Million dollars as of 2025-05-03. Jean Jacques Bienaime is the Director of Biomarin Pharmaceutical Inc and owns about 722,527 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $45 Million. Jean Jacques Bienaime is the Director of Incyte Corp and owns about 8,646 shares of Incyte Corp (INCY) stock worth over $540,634. Jean Jacques Bienaime is also the Director of Immunome Inc and owns about 31,415 shares of Immunome Inc (IMNM) stock worth over $278,023. Besides these, Jean Jacques Bienaime also holds Immunic Inc (IMUX) . Details can be seen in Jean Jacques Bienaime's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jean Jacques Bienaime has not made any transactions after 2025-03-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jean Jacques Bienaime
Jean Jacques Bienaime Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jean Jacques Bienaime owns 6 companies in total, including Incyte Corp (INCY) , Biomarin Pharmaceutical Inc (BMRN) , and Immunic Inc (IMUX) among others .
Click here to see the complete history of Jean Jacques Bienaime’s form 4 insider trades.
Insider Ownership Summary of Jean Jacques Bienaime
Ticker | Company | Transaction Date | Type of Owner |
---|---|---|---|
INCY | Incyte Corp | 2020-11-10 | director |
BMRN | Biomarin Pharmaceutical Inc | 2024-05-10 | director & Chief Executive Officer |
IMUX | Immunic Inc | 2018-09-24 | director |
![]() | ![]() | 2014-05-16 | director |
![]() | ![]() | 2012-02-07 | director |
![]() | ![]() | 2025-03-25 | director |
Jean Jacques Bienaime Latest Holdings Summary
Jean Jacques Bienaime currently owns a total of 4 stocks. Among these stocks, Jean Jacques Bienaime owns 722,527 shares of Biomarin Pharmaceutical Inc (BMRN) as of May 10, 2024, with a value of $45 Million and a weighting of 98.21%. Jean Jacques Bienaime owns 8,646 shares of Incyte Corp (INCY) as of November 10, 2020, with a value of $540,634 and a weighting of 1.18%. Jean Jacques Bienaime also owns 31,415 shares of Immunome Inc (IMNM) as of March 25, 2025, with a value of $278,023 and a weighting of 0.61%. The other 1 stocks Immunic Inc (IMUX) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Jean Jacques Bienaime
Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
BMRN | Biomarin Pharmaceutical Inc | 2024-05-10 | 722,527 | 62.03 | 44,818,350 |
INCY | Incyte Corp | 2020-11-10 | 8,646 | 62.53 | 540,634 |
IMNM | Immunome Inc | 2025-03-25 | 31,415 | 8.85 | 278,023 |
IMUX | Immunic Inc | 2018-09-24 | 463 | 1.15 | 532 |
Holding Weightings of Jean Jacques Bienaime
Jean Jacques Bienaime Form 4 Trading Tracker
According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 39 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years, including 0 buys and 39 sells. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 40,000 shares on May 10, 2024, which brought Jean Jacques Bienaime around $3 Million.
According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 1 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Incyte Corp is the sale of 798 shares on November 10, 2020, which brought Jean Jacques Bienaime around $66,234.
According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 4 transactions in Immunome Inc (IMNM) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Immunome Inc is the acquisition of 7,800 shares on March 25, 2025, which cost Jean Jacques Bienaime around $60,684.
More details on Jean Jacques Bienaime's insider transactions can be found in the Insider Trading History of Jean Jacques Bienaime table.Insider Trading History of Jean Jacques Bienaime
- 1
Jean Jacques Bienaime Trading Performance
GuruFocus tracks the stock performance after each of Jean Jacques Bienaime's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jean Jacques Bienaime is 22.99%. GuruFocus also compares Jean Jacques Bienaime's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jean Jacques Bienaime within 3 months outperforms 27 times out of 33 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jean Jacques Bienaime's insider trading performs compared to the benchmark.
Performance of Jean Jacques Bienaime
Jean Jacques Bienaime Ownership Network
Ownership Network List of Jean Jacques Bienaime
Ownership Network Relation of Jean Jacques Bienaime

Jean Jacques Bienaime's Executive Compensation Overview
Company | Year | Salary($) | Bonus($) | Stock Awards($) | Option Awards($) | Equity Awards($) | Non-Equity Incentive Plan($) | All Other Compensation($) | Change in Pension and Deferred Comp($) | Total($) |
---|---|---|---|---|---|---|---|---|---|---|
Biomarin Pharmaceutical Inc | 2023 | 1,479,423 | N/A | 15,949,610 | 2,370,990 | N/A | 1,668,000 | 507,997 | N/A | 21,976,020 |
![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Jean Jacques Bienaime Owned Company Details
What does Incyte Corp do?
Who are the key executives at Incyte Corp?
Jean Jacques Bienaime is the director of Incyte Corp. Other key executives at Incyte Corp include See Remarks Barry P Flannelly , EVP & General Counsel Sheila A. Denton , and EVP & Chief Medical Officer Steven H Stein .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Jean Jacques Bienaime made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net sale of 52,105 shares made by Barry P Flannelly , a net sale of 4,624 shares made by Thomas Tray , and a net sale of 31,325 shares made by Steven H Stein .
In summary, during the past 3 months, insiders sold 34,475 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 34,475 shares. During the past 18 months, 133,443 shares of Incyte Corp (INCY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 133,443 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Jean Jacques Bienaime Mailing Address
Above is the net worth, insider trading, and ownership report for Jean Jacques Bienaime. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jean Jacques Bienaime's mailing address is: Palo Alto Ca 94304.